Compound profile
LL-37
Limited human dataAlso known as: Cathelicidin LL-37 · hCAP-18 C-terminal peptide
The only human cathelicidin antimicrobial peptide, naturally released at wound margins during healing. Studied as a synthetic topical treatment for hard-to-heal chronic wounds, giving it more human RCT support than most "recovery peptide" research chemicals.
Overview
LL-37 is the only cathelicidin antimicrobial peptide that humans produce. Cathelicidins are a family of peptides found across many mammals that form part of the innate immune system, the body's first line of defense against infection, and LL-37 is the sole member encoded in the human genome. It gets its name from the fact that it is 37 amino acids long and begins with two leucine residues.
The peptide is not made in its active form directly. It is cleaved from a larger precursor protein called hCAP-18, which is itself the product of the CAMP gene, through proteolytic processing that releases the mature LL-37 peptide. It is stored in and released from neutrophils, a type of white blood cell, and is also produced by skin cells, epithelial cells lining the airways and gut, and other tissues, particularly at sites of injury or infection.
Bengt Agerberth's group first characterized the peptide in 1995, and a separate group led by Gudmundsson followed shortly after with work describing the gene and processing pathway. Since then, LL-37 has been studied for its direct antimicrobial activity against bacteria, and separately, for its role in wound healing, where it is released at the margins of healing wounds. That second role has led to human clinical trials of synthetic, topical LL-37 as a treatment for chronic wounds, giving it more direct human evidence than most peptides discussed as recovery compounds online.
Mechanism (plain language)
A cationic, amphipathic peptide with direct antimicrobial activity plus separate roles in immune modulation, angiogenesis, and keratinocyte/fibroblast signaling that drive re-epithelialization during wound healing.
How it works
LL-37's antimicrobial activity comes from its physical structure. It carries a strong net positive charge and folds into an amphipathic shape, meaning one face of the molecule is water loving and the other is fat loving. That structure lets it insert into and disrupt the negatively charged membranes of bacteria, a fairly blunt, mechanical form of killing that is harder for bacteria to develop resistance against compared with drugs that target a single protein.
Beyond direct killing, LL-37 acts as a signaling molecule in its own right. It attracts and activates immune cells, including neutrophils, monocytes, and T cells, and it promotes angiogenesis, the growth of new blood vessels, at sites of tissue damage. In skin and wound biology specifically, research describes it acting on keratinocytes and fibroblasts, the cells responsible for closing a wound, encouraging their migration and proliferation so the wound re-epithelializes, meaning the skin surface reforms, more quickly. This dual role, killing microbes directly while also orchestrating parts of the healing response, is why it shows up in both infection and wound repair research.
What research suggests
A first-in-man randomized, placebo-controlled trial in hard-to-heal venous leg ulcers found faster healing at low-to-moderate topical doses versus placebo; a separate diabetic foot ulcer RCT also reported improved healing markers. Effects were dose-dependent and did not hold at the highest tested dose.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Faster healing in chronic wounds
A first-in-man randomized, placebo-controlled trial in hard-to-heal venous leg ulcers reported considerably faster healing rates at low-to-moderate topical doses compared with placebo.
Diabetic foot ulcer healing markers
A separate randomized trial in diabetic foot ulcers reported improved healing markers with topical LL-37 treatment.
Broad-spectrum antimicrobial activity
Laboratory research consistently shows activity against a wide range of gram-positive and gram-negative bacteria, a mechanical mode of action that is less prone to classic antibiotic resistance.
Angiogenesis and re-epithelialization signaling
Preclinical studies describe LL-37 promoting new blood vessel growth and skin cell migration during wound regeneration.
Uncertainties & risks
Human evidence is specific to topical treatment of chronic wounds in patients with impaired healing, not systemic or injectable use, and not evidence for general "recovery" claims in healthy athletes. Not an approved drug; trial sizes remain modest.
The human data for LL-37 is real but narrow. The clinical trials that exist studied topical application in patients with impaired wound healing, specifically venous leg ulcers and diabetic foot ulcers, not systemic or injectable use, and not general recovery claims in healthy people. Interestingly, the venous leg ulcer trial found the effect was dose-dependent in an unusual way: benefit showed up at low and moderate doses but did not hold at the highest dose tested, a pattern worth taking seriously rather than assuming more is simply better. LL-37 is not an approved drug in any form, and the trials that exist are still relatively small by pharmaceutical standards. As an endogenous peptide the body already produces, it also plays roles that are still being worked out, including some evidence in immunology research that dysregulated LL-37 activity may contribute to certain inflammatory and autoimmune conditions, a reminder that more of a naturally occurring signaling peptide is not automatically better. People encountering LL-37 as a research chemical should recognize that the encouraging data is specific to a topical, clinically supervised context in patients with a defined wound-healing impairment.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.